Tesevatinib

泰西伐替尼

Report date: 2025/01/15 13:14:39
NME

Base Information

Drug NameTesevatinib
Drug Alias NameTesevatinib tosylate特伐替尼tesevatinibumXL-647KD-020 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsVascular endothelial growth factor receptor inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2Vascular endothelial growth factor receptor +[4] 
Therapy Area/IndicationsBrain metastasesPolycystic Kidney, Autosomal RecessivePolycystic Kidney, Autosomal Dominant +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesExelixis Inc
China Registration ClassN/A

Develop Information

Active CompaniesKadmon Corporation Llc
Inactive CompaniesExelixis Inc
Active IndicationsPolycystic Kidney, Autosomal Dominant
Inactive IndicationsBrain metastasesPolycystic Kidney, Autosomal RecessiveNeoplasm Metastasis +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG